Secondary outcomes include measures of efficacy of NRL@ compared with placebo following @ weeks treatment ; safety and tolerability ; evaluation of plasma pharmacokinetics ; establishment of any pharmacokinetic/pharmacodynamic relationship to adverse events ; dose-response relationship ; the efficacy of NRL@ therapy at @ and @ weeks assessed by the Vaizey score ; and QoL using the Faecal Incontinence Quality of Life and the EQ-@D-@L Healthcare Questionnaires following @ and @ weeks NRL@ therapy .